- 1 Is ARRY a buy?
- 2 Will Array Technologies stock go up?
- 3 Is Array Technologies a buy?
- 4 Why is ARRY stock down?
- 5 Is Paya a good stock to buy?
- 6 Is Arry a good stock?
- 7 What does Array BioPharma do?
- 8 Is Arry a good stock to buy?
- 9 Who owns array technologies?
- 10 Who bought Array BioPharma?
- 11 Who bought array?
- 12 How many employees does array technologies have?
- 13 When was Array Technologies founded?
- 14 Who are array techs competitors?
Is ARRY a buy?
Out of 9 analysts, 2 (22.22%) are recommending ARRY as a Strong Buy, 1 (11.11%) are recommending ARRY as a Buy, 5 (55.56%) are recommending ARRY as a Hold, 0 (0%) are recommending ARRY as a Sell, and 1 (11.11%) are recommending ARRY as a Strong Sell. What is ARRY’s earnings growth forecast for 2021-2023?
Will Array Technologies stock go up?
Will Array Technologies stock price grow / rise / go up? Yes. The ARRY stock price can go up from 13.620 USD to 19.102 USD in one year.
Is Array Technologies a buy?
Investor Takeaway. Array Technologies has fallen hard since the earnings release, as management pulled guidance due to unforeseen rises in steel and shipping costs. Array is currently a Buy for investors who have a well-diversified portfolio and can accept near-term uncertainty.
Why is ARRY stock down?
Why Array Technologies Stock Crashed in 2021 Array’s stock plunged 46% the day after it released its first-quarter earnings for the period ended March 31, 2021. Array CEO Jim Fusaro addressed why earnings were lower than Array’s internal expectations, noting “higher than expected logistics costs.”
Is Paya a good stock to buy?
Paya has received a consensus rating of Buy.
Is Arry a good stock?
Array Biopharma Inc (NASDAQ:ARRY) is not the most popular stock in this group but hedge fund interest is still above average. Our calculations showed that top 5 most popular stocks among hedge funds returned 95.8% in 2019 and 2020, and outperformed the S&P 500 ETF (SPY) by 40 percentage points.
What does Array BioPharma do?
Array BioPharma Inc. (NASDAQ: ARRY) is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer.
Is Arry a good stock to buy?
Array Technologies has received a consensus rating of Buy. The company’s average rating score is 2.54, and is based on 7 buy ratings, 6 hold ratings, and no sell ratings.
Who owns array technologies?
Ron P. Corio
|Mr. James M. Fusaro||CEO & Director||N/A|
|Mr. Ron P. Corio||Founder & Director||N/A|
|Mr. Jeffrey P. Krantz||Chief Commercial Officer||N/A|
|Mr. Nipul A. Patel||Chief Financial Officer||N/A|
Who bought Array BioPharma?
Pfizer Inc. (NYSE:PFE) today announced the successful completion of its acquisition of Array BioPharma Inc., advancing breakthrough science for the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need.
Who bought array?
In June 2019, Pfizer acquired the company for approximately $11 billion.
How many employees does array technologies have?
Array Technologies, Inc. is located in Albuquerque, NM, United States and is part of the Hardware Manufacturing Industry. Array Technologies, Inc. has 230 total employees across all of its locations and generates $872.66 million in sales (USD).
When was Array Technologies founded?
Who are array techs competitors?
Array Technologies’s top competitors include Solaria, Ascent Solar Technologies, SoloPower and Sunpreme.